Biosimilars is a rapidly expanding industry

The biosimilars market set to reach $90 Billion by 2030.

Biosimilars Industry gets a boost from FDA

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

Secure your place

Next-generation biosimilars will reduce healthcare cost

New biosimilars will reduce the treatment cost of chronic disease by 15 to 20%

View the latest program

Expert Speakers to Date

Jeff Gilmore
cGMPnow
Amy Walker
4basebio
Divita Gilles
DIVINCELL
Jessica Kenison
Mass General Brigham Inc.
Amy Rappaport
Gritstone bio, Inc.
Madhavan Nallani
ACM Biolabs
Daniel Griffith Anderson
Massachusetts Institute of Technology
Dong Shen
RNAimmune
Alexander Bukreyev
University of Texas Medical Branch
Jasmin Samaras
MSD/UCL

Past Attendees

Nest Scientific USA
Food and Agriculture Organization of the United Nations
AIVITA Biomedical Inc.
Sanofi
Vaxcyte
7 Hills Pharma LLC
IDT Biologika GmbH
Moderna
CEPI
Quantoom Biosciences
Resilience
Vaxxinity
myNEO
Merck
Repligen Corporation

Who should attend

Biosimilars Research
Biosimilars Drug Development
Biosimilars Manufacturing
Biologics Technologies
Genetic Engineering
Biotechnology Research
Modalities Research
Translational Research
Biosimilars Delivery Platforms
Biological Engineering of Biologics
Bioinformatics
Cell Lines Development
Clinical Research and Development
Cost Reduction Strategies
Sales and Marketing Initiatives
Business Development
Clinical Trials and Approvals
Immunization Research & Development
Manufacturing Research & Innovation
Research and Development
Strategy, Projects, & Public Affairs
Legal and Compliance Work
Equipment Certification Services
News Reporting and Journalism

Why Attend

The Biosimilars & Biologics Summit 2024 is the only event of its kind to deliver leading market intelligence and industry presentations on the latest in biosimilars therapeutics that can be interchangeable with biologics to reduce healthcare costs and chronic disease management...…

The Premier Forum for Biosimilars and Biologics Technologies

Welcome to the Biosimilars & Biologics Summit 2024, where global pharmaceutical, biopharmaceutical, and biotech companies will meet with leading industry experts to explore the latest research and innovations in biosimilars and biologics and introduce new therapies for more accessible and better healthcare.

Global biosimilars manufacturers face huge challenges in modifying existing cell lines and manufacturing processes of reference products at a lower cost without compromising safety, quality, and efficacy. As several approved biologics go off-patent, biosimilars have emerged as less expensive treatment alternatives to comparable drugs for patients.

Modern biologic medicines have revolutionized how physicians treat chronic diseases such as cancer, diabetes, and autoimmune disorders. Today’s leaders are developing a new class of drugs, which can be interchangeable with biologics in terms of efficacy, side effects, immunogenicity, and reducing healthcare costs. Next-generation biosimilars will be developed through chemistry changes, formulation alteration, and innovative delivery.

Key topics on this year’s agenda include:

Emerging trends in developing biosimilars and biologic therapeutics
The role of biosimilars design in the development of new drug modalities
Exploring new technological advances for the enhanced production of biosimilars
Latest research in bioavailability and bioequivalence assessment of biologic drugs
Regulatory and IP strategies for new-to-market biosimilar-based therapeutics
Case studies, clinical trials, and pharmacometrics analysis for biosimilars development

The Biosimilars & Biologics Summit 2024 is set to become the world’s leading event exclusively for the biotech, pharmaceuticals, and biopharmaceutical industry to meet and collaborate with biosimilars technology experts, examine new technologies and technical know-how, and discuss the latest research and innovations, technical and commercial challenges involved in bringing new therapies to market.

Call for Presentation

If you would like to be a speaker at this event, please contact sean.collins@iQ-Hub.com, subject heading “Call for Papers – Biosimilars & Biologics Summit 2024”.

Book now
To secure your place at Biosimilars & Biologics Summit 2024 or if you require more information, please contact delegates@iQ-Hub.com.

Key topics for 2024:

Emerging trends in developing biosimilars and biologic therapeutics
Understand how the development of biosimilars improves access to therapeutic interventions and enhances healthcare affordability.
The role of biosimilars design in the development of new drug modalities
Achieve a deeper understanding of biosimilars as novel drug modalities beyond traditional small molecules, including RNA, complex peptides, proteins, glycoproteins, and antibodies.
Exploring new technological advances for the enhanced production of biosimilars
Learn how the latest research in upstream technology for enhanced production enabled biosimilar drugs as well-established therapeutic interventions.
Latest research in bioavailability and bioequivalence assessment of biologic drugs
Gain insights into statistical considerations in the design, bioavailability, safety, immunogenicity, and bioequivalence of biosimilars products.
Regulatory and IP strategies for new-to-market biosimilar-based therapeutics
Learn the key regulatory approaches and IP strategies for approval of biologics-based therapeutics to manage chronic disease in the emerging biosimilars market.
Case studies, clinical trials, and pharmacometrics analysis for biosimilars development
Hear from leading manufacturers and implement strategies that others in the industry use to ensure successful product development and challenges in bringing new therapies to market.

Subscribe for updates:

Testimonials

Excellent Speaker Line Up. Showcasing the Science and Results from across the Industry.
Anne Renton (Merck)
Well Organized and Great Discussions. Networking Opportunities Were Excellent.
Carolyn Dulney (Roche)
Provided a Great Learning Opportunity and Served as a Very Good Networking Event.
Mike Zimmer (Novartis)
I Loved the Show! Very Informative Conference and a Great Group of People.
Wensheng Du (GlaxoSmithKline)
Excellent Conference. Very Useful Information. Well Organized Event and Agenda Was Very Appropriate.
Barry Rosen (Sanofi)
Highly Informational Event with Lots of Opportunities to Engage with Other People from the Field.
Ying Wang (Johnson & Johnson)